This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Corcept, Optime move to dismiss parts of Teva's amended US antitrust complaint

( November 1, 2025, 00:21 GMT | Official Statement) -- MLex Summary: Corcept Therapeutics and Optime Care asked a US judge to dismiss monopolization claims from Teva Pharmaceuticals. In a joint partial motion to dismiss the second amended complaint, Corcept and Teva noted that the judge, in her order granting in part their motion to dismiss Teva's first amended complaint, "substantially narrowed Teva’s case" and significantly limited "the conduct that Teva could pursue as well as the potential relief that Teva could even hope to obtain." The defendants argued that Teva chose to file a third complaint, but "rather than cure the deficiencies that Defendants and this Court previously identified, Teva’s Second Amended Complaint doubles down on them."See court document. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections